Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab
| Autor: | Falk Hiepe, Andreas Radbruch, Imtiaz M Mumtaz, Gerd-Rüdiger Burmester, Kay-Geert A. Hermann, Rolf Keitzer, Frank Buttgereit, Anne Bruns, Bimba F. Hoyer, Konstanze Loddenkemper, Claudia Sengler, Sofiane Maza |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Adolescent Immunology B-Lymphocyte Subsets medicine.disease_cause Severity of Illness Index General Biochemistry Genetics and Molecular Biology CD19 Lymphocyte Depletion Autoimmunity Antibodies Monoclonal Murine-Derived Young Adult Rheumatology B cell homeostasis medicine Immunology and Allergy Homeostasis Humans Lupus Erythematosus Systemic Lymphocyte Count B cell Aged CD20 Lupus erythematosus biology business.industry Middle Aged medicine.disease Takayasu Arteritis medicine.anatomical_structure Treatment Outcome Monoclonal biology.protein Drug Evaluation Rituximab Female business Immunosuppressive Agents medicine.drug |
| Zdroj: | Annals of the rheumatic diseases. 71(1) |
| ISSN: | 1468-2060 |
| Popis: | IntroductionTakayasu arteritis (TA) is a large vessel vasculitis involving the aorta and its major branches. T cell-mediated autoimmunity is thought to play a major role in its pathogenesis, while the role of B cells is still unclear.MethodsB cell subsets in the peripheral blood of 17 patients with TA were analysed and compared with nine patients with active systemic lupus erythematosus (SLE) and nine healthy controls by flow cytometry. Based on these findings, three patients with active refractory TA were treated with B cell depletion therapy (BCDT) using monoclonal anti-CD20 antibodies (rituximab).ResultsThe absolute number and frequency of peripheral blood CD19+/CD20−/CD27high antibody-secreting cells in patients with active TA was significantly higher than in healthy donors. As in active SLE, the majority of these cells are newly generated plasmablasts which significantly correlated with TA activity. Three patients with active refractory TA and expansion of plasmablasts were successfully treated with BCDT, which resulted in remission.ConclusionDisturbances of B cell homeostasis may be critical in TA. Circulating plasmablasts could be a useful biomarker of disease activity and a tool for selecting appropriate candidates for BCDT. B cells and plasmablasts/plasma cells may therefore represent novel targets for effective therapies for TA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|